HCM
HUTCHMED (China) Limited
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$14.09
−0.14%Year over year
Reported trailing growth
- Revenue
- -8.8%
- EBITDA
- —
- EBIT
- -76.6%
- EPS
- -96.4%
- Free cash flow
- +120.0%
- Operating cash flow
- +162.8%
Forward estimates
Based on analyst estimates
- Revenue
- +42.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.9%
- EBITDA
- -31.9%
- EBIT
- -25.2%
- Net income
- +113.2%
- EPS
- +110.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026